[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647201":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":27,"responsibleParty":42,"collaborators":27,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":27,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":27,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":65,"whyStopped":27,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":27},{"fullName":5,"class":6},"University of Florida","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"AIH + placebo","PLACEBO_COMPARATOR","Participants will receive a methylcellulose capsule identical in appearance to the experimental treatment, followed by acute intermittent hypoxia",[13,14],"Drug: Placebo","Other: Acute Intermittent Hypoxia (AIH)",{"label":16,"type":17,"description":18,"interventionNames":19},"AIH + Istradefylline","EXPERIMENTAL","Participants will receive 20 mg, followed by acute intermittent hypoxia",[20,14],"Drug: Istradefylline 20 mg",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Istradefylline 20 mg","Participants will receive 20 mg istradefylline active treatment, followed by acute intermittent hypoxia",[16],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Placebo","Participants will receive a methylcellulose capsule identical in appearance to the active treatment, followed by acute intermittent hypoxia",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Acute Intermittent Hypoxia (AIH)","Short periods (\\~1 minute) of breathing lower-oxygen gas, separated by periods (\\~1 minute) of breathing normal oxygen air.",[16,9],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Ushna Khan, MD","CONTACT","352-273-6855","ushnakhan@ufl.edu",{"type":43,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100647201","phase-1-enhancing-rehabilitation-in-aging-study-eras-100647201",false,"NCT07704385","Enhancing Rehabilitation in Aging Study (ERAS)","Inclusion Criteria:\n\n* Aged 40-79 years Non-smokers Ambulatory in the community Do not require assistance to complete activities of daily living\n\nExclusion Criteria:\n\n* Restrictive or obstructive lung conditions Pregnancy Active respiratory infections Use of antibiotics in the last 4 weeks Symptomatic cardiac disease BMI \\>35 kg\u002Fm2 Seizure disorder or progressive neurological condition Uses positive pressure mechanical ventilation when awake and upright, or oxygen assistance at any time",true,"ALL","40 Years","79 Years",{"count":55,"type":56},38,"ESTIMATED","INTERVENTIONAL",[59,60],"PHASE1","PHASE2","Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.",[63],"Adults",[63],"NOT_YET_RECRUITING","2026-07-10",{"date":68,"type":69},"2026-07-15","ACTUAL",{"date":71,"type":56},"2026-10-01",{"date":73,"type":56},"2031-12-31",{"name":5,"class":6}]